[go: up one dir, main page]

MX2023003194A - Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables. - Google Patents

Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.

Info

Publication number
MX2023003194A
MX2023003194A MX2023003194A MX2023003194A MX2023003194A MX 2023003194 A MX2023003194 A MX 2023003194A MX 2023003194 A MX2023003194 A MX 2023003194A MX 2023003194 A MX2023003194 A MX 2023003194A MX 2023003194 A MX2023003194 A MX 2023003194A
Authority
MX
Mexico
Prior art keywords
dosage forms
tyk2 inhibitors
swellable
cores
swellable cores
Prior art date
Application number
MX2023003194A
Other languages
English (en)
Inventor
Sherif Ibrahim Farag Badawy
Umesh Kestur
Kyle Kyburz
Dory Koehler-King
Craig Allen Sather
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023003194A publication Critical patent/MX2023003194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma de dosificación de núcleo hinchable comprende una dispersión de 6-(ciclopropanoamido)-4-((2-metoxi-3-(1-metil-1H-1,2 ,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida amorfa.
MX2023003194A 2020-09-18 2021-09-17 Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables. MX2023003194A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063080030P 2020-09-18 2020-09-18
PCT/US2021/050928 WO2022061149A1 (en) 2020-09-18 2021-09-17 Dosage forms for tyk2 inhibitors comprising swellable cores

Publications (1)

Publication Number Publication Date
MX2023003194A true MX2023003194A (es) 2023-04-13

Family

ID=78135169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003194A MX2023003194A (es) 2020-09-18 2021-09-17 Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.

Country Status (11)

Country Link
US (1) US20240325388A1 (es)
EP (1) EP4213813A1 (es)
JP (1) JP2023541997A (es)
KR (1) KR20230069976A (es)
CN (1) CN116472044A (es)
AU (1) AU2021342517A1 (es)
BR (1) BR112023004824A2 (es)
CA (1) CA3192982A1 (es)
IL (1) IL301389A (es)
MX (1) MX2023003194A (es)
WO (1) WO2022061149A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020349524A1 (en) * 2019-09-18 2022-03-31 Bristol-Myers Squibb Company Dosage forms for Tyk2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
AP2002002553A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Hydrogel-driven Drug Dosoge Form.
CN1625397A (zh) * 2002-02-01 2005-06-08 辉瑞产品公司 胆固醇酯转移蛋白抑制剂的控制释放药物剂型
EP2119442A4 (en) * 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
CN101152158B (zh) * 2007-08-21 2010-05-26 浙江大学 一种药物的双层芯渗透泵片的制备方法
CA2890981C (en) 2012-11-08 2022-07-05 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses
ES2864450T3 (es) 2017-03-30 2021-10-13 Bristol Myers Squibb Co Proceso para la preparación de 6-(ciclopropanamido)-4-((2-metoxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-N-(metil-d3)piridazina-3-carboxamida
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
AU2020349524A1 (en) * 2019-09-18 2022-03-31 Bristol-Myers Squibb Company Dosage forms for Tyk2 inhibitors

Also Published As

Publication number Publication date
KR20230069976A (ko) 2023-05-19
AU2021342517A1 (en) 2023-05-11
IL301389A (en) 2023-05-01
JP2023541997A (ja) 2023-10-04
CA3192982A1 (en) 2022-03-24
EP4213813A1 (en) 2023-07-26
WO2022061149A1 (en) 2022-03-24
BR112023004824A2 (pt) 2023-04-18
CN116472044A (zh) 2023-07-21
US20240325388A1 (en) 2024-10-03

Similar Documents

Publication Publication Date Title
PH12022551424A1 (en) Kras g12c inhibitors.
MX2022010496A (es) Forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metoxi-3- (1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazin-3-carboxamida.
MX2023003194A (es) Formas de dosificacion para inhibidores de tirosina cinasa 2 (tyk2) que comprenden nucleos hinchables.
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
CA2490907A1 (en) Amide derivative
ZA202107668B (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
MXPA05011666A (es) Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.
NZ752918A (en) Treatment of prostate cancer
EP3860571A4 (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
MX2023013538A (es) Metodos para tratar la depresion y la ansiedad.
MX2023013536A (es) Metodos para tratar la depresion y la ansiedad.
UY39229A (es) Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
PH12014501062B1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl )-2-pyrimidinyl ]amino]-n-[5-(4-methyl-1h-1midazol-1yl)-3-(trifluoromethyl)phenyl]benzamide formulation
IL304597A (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
AU2022214313A9 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide
SG165178A1 (en) Novel composition comprising rosiglitazone and another antidiabetic agent
IL198630A0 (en) Pyrimidyl derivatives as protein kinase inhibitors
SE0202461D0 (sv) Novel compounds
WO2022093610A8 (en) Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate
MX2023002086A (es) Formulaciones topicas estables de 1(r)-4-(5-(4-metoxi-3-propoxifen il)piridin-3-il)-1,2-oxaborolan-2-ol.
PL2089030T3 (pl) Środek do zapobiegania lub leczenia uzależnienia od alkoholu lub uzależnienia od narkotyków
MY144899A (en) Mirtazapine salts
PT1631291E (pt) Uso de inibidores tirosina quinase no tratamento de diabetes
MX2023002996A (es) Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria.